Sulfonamides

Antiviral Agents
No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir
Matthew P. Kosloski, Weihan Zhao, Armen Asatryan, Jens Kort, Pierre Geoffroy, Wei Liu
Antiviral Agents
Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus
Jan Martin Berke, Pascale Dehertogh, Karen Vergauwen, Ellen Van Damme, Wendy Mostmans, Koen Vandyck, Frederik Pauwels
Pharmacology
Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses
Jennifer R. King, Amit Khatri, Roger Trinh, Rolando M. Viani, Bifeng Ding, Jiuhong Zha, Rajeev Menon
Antiviral Agents
Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy
Sidonie Lambert-Niclot, Gilles Peytavin, Claudine Duvivier, Catherine Poirot, Michèle Algarte-Genin, Sophie Pakianather, Jean-Luc Meynard, Marc-Antoine Valantin, Jean-Michel Molina, Philippe Flandre, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin
Antiviral Agents
Pharmacokinetics of Darunavir/Ritonavir and Rifabutin Coadministered in HIV-Negative Healthy Volunteers
Vanitha Sekar, Ludo Lavreys, Tom Van de Casteele, Cindy Berckmans, Sabrina Spinosa-Guzman, Tony Vangeneugden, Martine De Pauw, Richard Hoetelmans
Mechanisms of Resistance
High-Resolution Crystal Structure of the Subclass B3 Metallo-β-Lactamase BJP-1: Rational Basis for Substrate Specificity and Interaction with Sulfonamides
Jean-Denis Docquier, Manuela Benvenuti, Vito Calderone, Magdalena Stoczko, Nicola Menciassi, Gian Maria Rossolini, Stefano Mangani
Antiviral Agents
Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy
Eva Poveda, Lourdes Anta, José Luis Blanco, José Luis Casado, Félix Gutiérrez, Federico García, Juan Luis Gómez-Sirvent, José Antonio Iribarren, Vincent Soriano, Carmen de Mendoza
and on behalf of the Resistance Platform of the Spanish AIDS Research Network (ResRIS)
Pharmacology
Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy Volunteers
Gaik H. Soon, Ping Shen, Eu-Leong Yong, Paul Pham, Charles Flexner, Lawrence Lee
Antiviral Agents
Predicting Tipranavir and Darunavir Resistance Using Genotypic, Phenotypic, and Virtual Phenotypic Resistance Patterns: an Independent Cohort Analysis of Clinical Isolates Highly Resistant to All Other Protease Inhibitors
Annie Talbot, Philip Grant, Jonathan Taylor, Jean-Guy Baril, Tommy Fulisma Liu, Hugues Charest, Bluma Brenner, Michel Roger, Robert Shafer, Régis Cantin, Andrew Zolopa
Antiviral Agents
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
Oliver Lenz, Thierry Verbinnen, Tse-I Lin, Leen Vijgen, Maxwell D. Cummings, Jimmy Lindberg, Jan Martin Berke, Pascale Dehertogh, Els Fransen, Annick Scholliers, Katrien Vermeiren, Tania Ivens, Pierre Raboisson, Michael Edlund, Susan Storm, Lotta Vrang, Herman de Kock, Gregory C. Fanning, Kenneth A. Simmen

Main menu

User menu

Search

Sulfonamides

Pages